Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.60 |
| ▸ | HTR2C | P28335 | 7/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | HTR6 | P50406 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KHK | P50053 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6739875 | 0.98 | HTR2C (0.61) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| SCHEMBL6161997 | 0.91 | KHK (0.54) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| SCHEMBL14704894 | 0.89 | QDPR (0.54) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| Hydrochloric Acid SCHEMBL16874680 | 0.88 | QDPR (0.52) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| Water SCHEMBL7966495 | 0.86 | QDPR (0.58) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28142548 | 0.85 | PNMT (0.51) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| SCHEMBL14085315 | 0.83 | QDPR (0.43) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| SCHEMBL6161994 | 0.82 | HTR6 (0.53) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| SCHEMBL7394377 | 0.82 | HTR2C (0.60) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| Hydrochloric Acid SCHEMBL4789235 | 0.80 | HTR2C (0.61) | QDPRHTR2CSIGMAR1HTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742047-B1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-05-12 | — | — | EP | disclosed |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| EP-3207928-B1 | COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES | HYUNDAI PHARM CO LTD (KR) | 2021-03-10 | — | — | EP | disclosed |
| US-10821110-B2 | Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | HYUNDAI PHARM CO., LTD. (KR) | 2020-11-03 | — | — | US | disclosed |
| US-20200297742-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200297742-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| CN-106715409-B | Complex preparation for preventing or treating metabolic diseases comprising 3- (4- (benzyloxy) phenyl) -4-hexynoic acid derivative and other active ingredients | 现代药品株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-111423408-A | Compound preparation for preventing or treating metabolic diseases | 现代药品株式会社 | 2020-07-17 | — | — | CN | disclosed |
| EP-3677578-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Bristol-Myers Squibb Company (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-0937715-A1 | TETRAHYDROBENZINDOLE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1999-08-25 | — | — | EP | disclosed |
| EP-0886636-A1 | NOVEL PIPERIDINES DERIVED FROM 1-/(PIPERAZIN-1-YL)ARYL(OXY/AMINO)CARBONYL/-4-ARYL-PIPERIDINE AS SELECTIVE 5-HT-1D.BETA. RECEPTOR ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 1998-12-30 | — | — | EP | disclosed |
| US-5700809-A | Pyrrolo-pyridine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1997-12-23 | — | — | US | disclosed |
| WO-1997028140-A1 | NOVEL PIPERIDINES DERIVED FROM 1-/(PIPERAZIN-1-YL)ARYL(OXY/AMINO)CARBONYL/-4-ARYL-PIPERIDINE AS SELECTIVE 5-HT1Db RECEPTOR ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 1997-08-07 | — | — | WO | disclosed |
| EP-0687267-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020459-A2 | PYRROLO-PYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| US-5036075-A | Serotonin antagonists | RHONE-POULENC SANTE (FR) | 1991-07-30 | — | — | US | disclosed |
| US-5021420-A | Antiserotonine agents; central nervous system, gastroin-testinal and cardiovascular disorders | RHONE-POULENC SANTE (FR) | 1991-06-04 | — | — | US | disclosed |
| US-4166853-A | Antihypertensive 7-trifluoromethyl-4-aminoquinolones | THE UPJOHN COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
| US-3951987-A | PSYCHOSEDATIVE | HOFFMANN-LA ROCHE INC. (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297742-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GRIN2C, GRIN3A, GRIN2B | QDPR 546/4885HTR2C 25/4885SIGMAR1 111/4885 |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | QDPR 492/4885HTR2C 94/4885SIGMAR1 76/4885 |
| US-10821110-B2 | Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | SLC5A2, SLC5A1, DPP4 | QDPR 1837/4885HTR2C 586/4885SIGMAR1 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.